FLUTAMIDE TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER

氟他胺治疗经前烦躁不安

• 批准号: 7378401
• 负责人: MARGARET ALTEMUS
• 金额: $ 6.16万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378401
• 关键词: FLUTAMIDE; TREATMENT; PREMENSTRUAL; DYSPHORIC; DISORDER

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aim of this study is to determine whether androgen receptor blockade using the androgen receptor antagonist flutamide will relieve symptoms of premenstrual dysphoric disorder. A placebo controlled, parallel design pilot study will be conducted. 64 subjects will be recruited, which will allow detection of a large effect of flutamide treatment, and provide data to estimate smaller effect sizes for use in design of a larger-scale study, if indicated. Tolerability of flutamide treatment will also be estimated by comparison of side effects between flutamide and placebo treatment.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的主要目的是确定使用雄激素受体拮抗剂氟替卡松阻断雄激素受体是否能缓解经前焦虑障碍的症状。将进行一项安慰剂对照、平行设计的初步研究。将招募64名受试者，这将允许检测氟他胺治疗的巨大效应，并提供数据来估计较小的效应量，以用于设计更大规模的研究（如果有必要）。还将通过比较氟替卡松和安慰剂治疗之间的副作用来估计氟替卡松治疗的耐受性。